Growth Hormone and Prader-Willi Syndrome

Aaron L. Carrel, Phillip D.K. Lee, Harriette R. Mogul

Research output: Chapter in Book/Report/Conference proceedingChapter


In 2000, biosynthetic growth hormone (GH) became the first medication to receive regulatory approval for treatment of PWS. As of this writing, biosynthetic GH (somatropin and somatropin biosimilars) continues to be the only approved medication for PWS, with published evidence demonstrating significant benefits for children and adults with PWS [1]. This chapter presents a comprehensive review of relevant physiology and pathophysiology of the GH system and GH treatment efficacy and safety in PWS.

Original languageEnglish (US)
Title of host publicationManagement of Prader-Willi Syndrome
Subtitle of host publicationFourth Edition
PublisherSpringer International Publishing
Number of pages22
ISBN (Electronic)9783030981716
ISBN (Print)9783030981709
StatePublished - Jan 1 2022
Externally publishedYes

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Growth Hormone and Prader-Willi Syndrome'. Together they form a unique fingerprint.

Cite this